European journal of clinical investigation
-
Reduction in overweight and obesity management have been shown to be important in the treatment of diabetes. Even modest weight loss produces important metabolic benefits if maintained over the long term. Thus a pharmacotherapeutic agent that could produce a maintained weight loss, and had a good safety profile, would revolutionize the treatment of type II (non-insulin-dependent) diabetes. ⋯ A 1-year treatment with orlistat also substantially prevented the conversion of impaired glucose tolerance into type II diabetes (conversion rate 2.6% in the orlistat group versus 10.4% in the placebo group). Encouraging results have also been reported from studies on orlistat and sibutramine in non-diabetics, with beneficial effects seen for weight loss and other diabetes risk factors. Antiobesity pharmacotherapy therefore appears to offer a realistic option for the prevention of diabetes, although further studies are required to determine its efficacy.
-
Eur. J. Clin. Invest. · Sep 1998
ReviewDiet, exercise and behavioural intervention: the nonpharmacological approach.
Behaviour is an important factor in both the aetiology and treatment of obesity. Successful long-term weight management ultimately depends on the ability of patients to change their behaviour patterns, particularly with regard to diet and exercise. ⋯ Four examples of lifestyle changes are discussed in this paper: exercise; relapse prevention; the concept of a reasonable weight; and attribution theory. Behavioural therapy should be an integral part of a multifaceted approach for managing obesity and associated conditions, such as type II (non-insulin-dependent) diabetes.